Daniel Tassé

Mr. Tassé is Chief Executive Officer of DBV Technologies SA. Previously, Mr. Tassé was Chairman and Chief Executive Officer of Alcresta Therapeutics, Inc., as well as Chairman and Chief Executive Officer of Ikaria, Inc., prior to its acquisition by Mallinckrodt Pharmaceuticals. He has also held leadership roles at Baxter International Inc. and GlaxoSmithKline plc.

Mr. Tassé earned a B.S. in biochemistry from the University of Montreal. He currently serves as a director at Indivior PLC and previously served as a director at Bellerophon Therapeutics, Inc. Mr. Tassé has previously been a member of the Healthcare Leadership Council, the Health Section Governing Board of the Biotechnology Innovation Organization (BIO), and the board of directors of the Pharmaceutical Research and Manufacturers of America (PhRMA).